KRAS and colorectal carcinoma: Regarding the potential of anti-EGFR therapy (see Figure 3), we did not find evidence of significant dysregulation of EGFR gene in CRC tissue in general or depending on the KRAS mutation status that could suggest a beneficial effect of anti-EGFR therapy at least in this population.